The disorder in question is cerebral cavernous malformation, or CCM, a condition in which clusters of abnormally dilated capillary channels form in the brain and spinal cord. These fragile vessels lack the normal structural support of healthy capillaries, making them prone to leakage and bleeding. Some people carry the lesions for life without ever knowing they have them, while others experience seizures, focal neurological deficits, debilitating headaches, or catastrophic intracranial hemorrhage. When the condition runs in families, it follows an autosomal dominant inheritance pattern, meaning a child of an affected parent has a fifty percent chance of inheriting the predisposition. Three genes account for the overwhelming majority of genetically confirmed familial cases: KRIT1 (also known as CCM1), CCM2, and PDCD10, with KRIT1 variants responsible for the largest share.

The new report centers on a fourteen-year-old boy who arrived at a pediatric neurology clinic after a focal epileptic seizure marked by numbness in his left arm. His medical history contained an unusual clue. Five months earlier, surgeons had removed a painful, progressively enlarging mass from his right parietal scalp—a lesion that had been palpable for roughly two years before accelerating in growth. Skull radiography and bone-window computed tomography revealed a well-circumscribed expansile lesion of the parietal bone with radiating trabecular striations, a classic spoke-wheel pattern pointing to a calvarial intraosseous hemangioma. Magnetic resonance imaging confirmed strong contrast enhancement of the diploic lesion, and histopathological examination of the resected bone specimen was compatible with hemangioma.

But the skull mass was only the beginning. Susceptibility-weighted imaging, a magnetic resonance sequence exquisitely sensitive to the blood breakdown products that accumulate in cavernous malformations, revealed multiple small punctate hypointense foci scattered throughout the cerebral parenchyma, along with bilateral lesions in the cerebellum. Spinal magnetic resonance imaging then uncovered a cervical intramedullary cavernous malformation, appearing as a central hyperintense core wrapped in a dark rim of hemosiderin—the iron-containing residue of prior microbleeds. Together, the multifocal brain and spinal findings strongly suggested a familial cavernous malformation syndrome rather than isolated sporadic disease.

The family history deepened the suspicion. The boy’s father had died suddenly at forty-one years of age from an intracerebral hemorrhage, a catastrophic event entirely consistent with an undiagnosed cavernous malformation bleed. Because the father was deceased, no genetic material was available to confirm his status, but the clinical picture weighed heavily in the investigators’ reasoning. Prompted by the combination of multifocal lesions, spinal involvement, and the fatal paternal hemorrhage, the team turned to whole-exome sequencing to search for a genetic culprit.

Sequencing delivered a clear answer. The boy carried a heterozygous duplication designated NM_004912.4: c.2dup in the KRIT1 gene—a single duplicated nucleotide at the second position of the coding sequence, directly disrupting the canonical translation initiation codon. The variant is predicted to trigger a frameshift from the very first coding codon, generating a premature termination signal at amino acid thirty-one, denoted p.(Met1IlefsTer31). The consequence is stark: the truncated protein would lack all major functional domains, including the ankyrin repeats, the FERM domain, the PDZ-binding motif, and the C-terminal regions that allow KRIT1—whose protein product is known as malcavernin—to stabilize endothelial cell junctions. Under current American College of Medical Genetics and Genomics criteria, the variant earned a likely pathogenic classification on the strength of four lines of evidence: the predicted loss-of-function effect in a gene where such loss is an established disease mechanism, its complete absence from population databases such as gnomAD, a phenotype highly specific to familial CCM, and clean segregation within the family. No pathogenic variants were found in CCM2 or PDCD10.

Segregation analysis revealed the variant’s reach. The proband’s sixteen-year-old brother, despite being entirely free of seizures, headaches, or any neurological symptoms, carries the identical variant—and brain magnetic resonance imaging showed multiple cavernous malformations in his parenchyma, though his spinal cord appeared uninvolved. Their mother, clinically healthy, does not carry the variant, which fits with the father being the presumed source of the mutation. A structured search of the medical literature and variant databases, including PubMed, ClinVar, and the Human Gene Mutation Database, failed to identify any previously reported individual or family carrying KRIT1 c.2dup or a closely related translation-initiation frameshift variant, making this the first documentation of the change.

The molecular biology underlying KRIT1-associated disease helps explain why the variant is so consequential. KRIT1 functions within the Rap1–KRIT1–CCM2 signaling complex, a molecular apparatus that maintains the integrity of endothelial tight junctions and restrains vascular permeability. Pathogenic variants typically cause disease through haploinsufficiency—one working copy of the gene is simply not enough to keep the vascular lining stable. Variants that sabotage the translation start site are particularly efficient at abolishing protein production, and previously reported initiation-region and early truncating KRIT1 variants, such as c.1A>G, c.143dup, c.152_155del, and several nonsense changes, all converge on the same mechanism: disrupted translation, premature truncation, or nonsense-mediated mRNA decay that eliminates the faulty transcript. The c.2dup variant stands out because it simultaneously destroys the initiation codon and introduces an immediate frameshift, a double hit predicted to eliminate functional protein entirely.

Perhaps the most clinically instructive aspect of the family is the striking variability among its members. One sibling lives with controlled epilepsy, intermittent headaches, and a history of an unusual skull tumor; the other is completely asymptomatic yet harbors multiple brain lesions visible only on susceptibility-weighted sequences; their father likely died of the condition’s most feared complication. This spectrum—from silent radiological disease to fatal hemorrhage within a single household—underscores a persistent limitation of genetic medicine: knowing the genotype does not reliably predict clinical severity, hemorrhagic risk, or long-term outcome in familial CCM. Age-dependent penetrance and variable expression complicate counseling and make lifelong surveillance essential even for people who feel perfectly well.

Management in the reported family followed current best practice, which remains largely phenotype-driven. The proband’s seizures responded well to levetiracetam, leaving him seizure-free for six months, while his intracranial lesions were placed under radiological surveillance rather than surgical treatment. His asymptomatic brother likewise required only structured clinical and radiological monitoring. Surgery is generally reserved for medically refractory epilepsy, recurrent hemorrhage, progressive neurological deficits, or readily accessible symptomatic lesions. Interestingly, the authors addressed the boy’s calvarial hemangioma directly, concluding that its coexistence with familial CCM is almost certainly incidental. Under the International Society for the Study of Vascular Anomalies classification, hemangiomas are proliferative vascular tumors, whereas cavernous malformations are slow-flow malformations of vascular morphogenesis—fundamentally different entities. A recent cohort study of 257 pediatric patients carrying 786 cerebral and 14 spinal cavernous malformations reported no concomitant hemangiomas, reinforcing the interpretation that the two findings in this boy are unrelated.

The authors acknowledge limitations, including the absence of genetic data from the deceased father, the lack of confirmatory Sanger sequencing—mitigated by exceptionally deep sequencing coverage exceeding 110-fold with more than 97 percent of target regions covered at twentyfold or greater—relatively short follow-up, and the lack of functional validation studies such as transcript or protein analyses. Even so, the convergence of high-quality sequencing, familial segregation, characteristic neuroimaging, and standardized variant interpretation makes a compelling case. The broader message for clinicians and families is unambiguous: integrating molecular diagnostics, cascade genetic testing of at-risk relatives, and susceptibility-weighted magnetic resonance imaging can identify silent carriers of KRIT1 variants before symptoms appear, opening a window for counseling, risk stratification, and monitoring that could one day prevent the kind of sudden, fatal hemorrhage that struck this family’s father.

Subject of Research: Familial cerebral cavernous malformation caused by a novel KRIT1 translation initiation-region frameshift variant

Article Title: Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant

Article References: Yayıcı Köken, Ö., Yanartaş, M. S., Aygün, H., Ceylan, A. C., Karaali, K., & Kazan, M. S. (2026). Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant. Molecular Genetics & Genomic Medicine, 14(9), Article e70304. https://doi.org/10.1002/mgg3.70304

Image Credits: AI Generated

DOI: 10.1002/mgg3.70304

Keywords: cerebral cavernous malformation, KRIT1, malcavernin, frameshift variant, whole-exome sequencing, familial CCM, susceptibility-weighted imaging, pediatric neurology, epilepsy, intracerebral hemorrhage, genetic testing, haploinsufficiency